OncoMatch/Clinical Trials/NCT05492123
Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer
Is NCT05492123 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Nivolumab 40 mg in 4 ml and Ipilimumab 200 MG in 40 ML for uterine cervical neoplasms.
Treatment: Nivolumab 40 mg in 4 ml · Ipilimumab 200 MG in 40 ML — A total of 112 patients with locally advanced cervical cancer will be randomized 1:1 to standard therapy with cisplatin-based chemoradiation or nivolumab-ipilimumab induction followed by cisplatin-based chemoradiation. The primary outcome will be 3-year disease-free survival.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Disease stage
Required: Stage FIGO STAGE IB2-IB3 NODE POSITIVE, STAGE IIB-IVA (FIGO)
cervical adenocarcinoma or squamous carcinoma FIGO Stage IB2-IB3 node positive or Stage IIB-IVA
Performance status
WHO/ECOG 0–1
Prior therapy
Cannot have received: chemotherapy
Cannot have received: immune checkpoint inhibitor
Cannot have received: radiation therapy
Lab requirements
Blood counts
WBC ≥ 2000/μL; Neutrophil count ≥ 1500/μL; Platelet count ≥ 100 x 10^3/μL; Hemoglobin ≥ 9.0 g/dL
Kidney function
Serum creatinine ≤ 1.5 x ULN unless creatinine clearance ≥ 40 mL/min
Liver function
AST/ALT ≤ 3.0 x ULN; Total bilirubin ≤ 1.5 x ULN (except Gilbert Syndrome: < 3.0 x ULN)
WBC count (WBC) < 2000/μL ; Neutrophil count < 1500/μL; Platelet count < 100 x 103/μL; Hemoglobin level < 9.0 g/dL; Serum creatinine > 1.5 x upper limit of normal (ULN) unless creatinine clearance is ≥ 40 mL/min; AST/ALT: > 3.0 x ULN; Total bilirubin > 1.5 x ULN (except participants with Gilbert Syndrome who must have a total bilirubin level of < 3.0 x ULN)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify